drugset / Trial / NCT04660890
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
RandomizedParallel-groupDouble-blindBasic science
Summary
This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.
Timeline
- Start
- 2020-12-12
- Primary completion
- 2021-03-16
- Completion
- 2021-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | — | Oral |
| Subject | Vemircopan | Small molecule | 120 mg | Oral |
| Subject | Vemircopan | Small molecule | 240 mg | Oral |
| Subject | Vemircopan | Small molecule | 360 mg | Oral |
Indications
No indication recorded.